文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

伴骨髓增生异常相关遗传学特征的急性髓系白血病患者接受异基因造血细胞移植:遗传学基础类别的相关性——代表EBMT急性白血病工作组的回顾性分析

Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT.
PubMed 文献 · Am J Hematol · 2025-03-10

该回顾性分析纳入2010至2022年首次完全缓解期接受异基因造血细胞移植的1152例骨髓增生异常相关AML患者,按国际共识分类分为MR-GM、TP53突变复杂核型、MR-CG和TP53突变非复杂核型四组;各组2年复发率、无白血病生存率、总生存率及无GVHD无复发生存率差异显著,多因素分析证实遗传学分组对移植结局有强影响。

要点

  • MR-AML按ICC分为MR-GM、MR-CG、TP53突变复杂核型及TP53突变非复杂核型四组。
  • 四组2年复发率分别为20.2%、29.2%、57.6%和44.6%,TP53突变复杂核型最高。
  • 多因素分析中MR-GM、MR-CG和TP53突变非复杂核型相对TP53突变复杂核型的LFS风险比分别为0.21、0.33和0.61。

核心结论

  • 本研究证实骨髓增生异常相关AML的遗传学分组对移植结局有强影响。

研究设计与样本

  • 代表EBMT急性白血病工作组的回顾性分析,纳入2010至2022年首次完全缓解期接受异基因造血细胞移植的1152例骨髓增生异常相关AML患者。
  • 按国际共识分类分为MR-GM 379例(33%)、TP53突变复杂核型328例(28%)、MR-CG 246例(21%)、TP53突变非复杂核型199例(17%)。
  • 中位年龄60岁,中位移植年份2020年;65%使用无关供者,61%使用减低强度预处理。

主要发现

  • 2年复发率在MR-GM、MR-CG、TP53突变非复杂核型和TP53突变复杂核型组分别为20.2%、29.2%、44.6%和57.6%。
  • 2年无白血病生存率在MR-GM、MR-CG、TP53突变非复杂核型和TP53突变复杂核型组分别为60%、55.3%、40.6%和20.2%。
  • 2年总生存率在MR-GM、MR-CG、TP53突变非复杂核型和TP53突变复杂核型组分别为65.7%、60.1%、47.1%和24.5%。
  • 2年无GVHD无复发生存率在MR-GM、MR-CG、TP53突变非复杂核型和TP53突变复杂核型组分别为46.9%、39.5%、31.9%和13.2%。
  • 多因素分析中,相对参考组TP53突变复杂核型AML,MR-GM、MR-CG和TP53突变非复杂核型的LFS风险比分别为0.21、0.33和0.61。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients (pts) with myelodysplasia-related AML (MR-AML) are now genetically recategorized, with three different groups in the International Consensus Classification: AML with mutated TP53 (TP53-AML), with myelodysplasia-related gene mutations (MR-GM AML), and with myelodysplasia-related cytogenetic abnormalities (MR-CG AML). Moreover, TP53-AML is determined by the presence of an additional complex karyotype (TP53-mut CK and non-CK AML, respectively). Nonetheless, the relevance of this classification to transplantation outcomes is largely unknown. We analyzed the outcomes of pts. with MR-AML undergoing allogeneic hematopoietic cell transplantation in first complete remission between 2010 and 2022 according to these genetic categories. Overall, 1152 patients were identified: 379 (33%), 328 (28%), 246 (21%), and 199 (17%) with MR-GM, TP53-mut CK, MR-CG, and TP53-mut non-CK AML, respectively. Median age was 60 years; median year of transplant was 2020. Unrelated donors and reduced-intensity conditioning were used in 65% and 61% of cases, respectively. Outcomes differed markedly among genetic categories, with an increasing relapse incidence (20.2%, 29.2%, 44.6%, and 57.6% at 2 years), and decreasing LFS (60%, 55.3%, 40.6%, and 20.2% at 2 years), overall survival (65.7%, 60.1%, 47.1%, and 24.5% at 2 years), and graft-versus-host disease-free, relapse-free survival (46.9%, 39.5%, 31.9%, and 13.2% at 2 years) in MR-GM, MR-CG, TP53-mut non-CK, and TP53-mut CK AML, respectively. These differences were confirmed in the multivariate analysis (hazard ratio for LFS: 0.21, 0.33 and 0.61 in MR-GM, MR-CG, and TP53-mut non-CK, with respect to reference TP53-mut CK AML group). This study confirms the strong impact of genetic grouping of MR-AML on transplant outcomes.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Esteve J, Nagler A, Labopin M, et al. Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT. Am J Hematol. 2025. PMID: 40062532. doi:10.1002/ajh.27647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。